<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/cc103.anc" start="2489" end="2494" sStart="2458" offset="31" sid="r7.1.use.v.0358" wn="1" wnkey="use%2:34:01::" annotator="jeneale" text="A MEDLINE search was conducted using databases from 1966 to May 1997." />
    <s path="[OANC]/data/written_2/technical/biomed/cc103.anc" start="26611" end="26622" sStart="null" offset="124" sid="r11.recommend.v.0553" wn="1" wnkey="recommend%2:32:01::" annotator="vebatchelder" text="Accordingly, on the basis of existing evidence, the use of dopamine to improve renal function cannot be recommended." />
    <s path="[OANC]/data/written_2/technical/biomed/cc103.anc" start="6042" end="6051" sStart="null" offset="155" sid="r11.recommend.v.0551" wn="1" wnkey="recommend%2:32:01::" annotator="anfahmy" text="Virtually all studies have used hydration (usually with 0.45% saline) in addition to the agent being tested and most authors recommend its use." />
    <s path="[OANC]/data/written_2/technical/biomed/cc103.anc" start="10129" end="10140" sStart="null" offset="105" sid="r11.recommend.v.0552" wn="1" wnkey="recommend%2:32:01::" annotator="adelpriore" text="Given these considerations, and in the absence of clinical data, diuretics cannot be recommended to prevent ATN." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/cc103.anc" start="251" end="256" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" annotator="veweser" text="It is generally defined as a &lt;b&gt;rapid&lt;/b&gt; decline (within hours to weeks) in glomerular filtration rate (GFR) and retention of nitrogenous waste products." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/cc103.anc" start="251" end="256" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" annotator="veweser" text="It is generally defined as a &lt;b&gt;rapid&lt;/b&gt; decline (within hours to weeks) in glomerular filtration rate (GFR) and retention of nitrogenous waste products." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/cc103.anc" start="251" end="256" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" annotator="elstickles" text="It is generally defined as a &lt;b&gt;rapid&lt;/b&gt; decline (within hours to weeks) in glomerular filtration rate (GFR) and retention of nitrogenous waste products." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/cc103.anc" start="251" end="256" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" annotator="comcgeetubb" text="It is generally defined as a &lt;b&gt;rapid&lt;/b&gt; decline (within hours to weeks) in glomerular filtration rate (GFR) and retention of nitrogenous waste products." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/cc103.anc" start="251" end="256" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" annotator="carichter" text="It is generally defined as a &lt;b&gt;rapid&lt;/b&gt; decline (within hours to weeks) in glomerular filtration rate (GFR) and retention of nitrogenous waste products." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/cc103.anc" start="251" end="256" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" annotator="carichter" text="It is generally defined as a &lt;b&gt;rapid&lt;/b&gt; decline (within hours to weeks) in glomerular filtration rate (GFR) and retention of nitrogenous waste products." />
    <s path="[OANC]/data/written_2/technical/biomed/cc103.anc" start="11753" end="11758" sStart="null" offset="24" sid="r9.level.n.0503" wn="2" wnkey="level%1:26:01::" annotator="cgozo" text="Among these is a recent level II study by Lherm et al [ 14] in which dopamine infusion failed to improve renal function in patients with sepsis except for transiently increasing creatinine clearance in patients without shock." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/cc103.anc" start="13263" end="13267" sStart="null" offset="0" sid="null" wn="4" wnkey="date%1:28:02::" annotator="veweser" text="Nonetheless, the available literature to &lt;b&gt;date&lt;/b&gt; does not support a survival benefit for this therapy." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/cc103.anc" start="13263" end="13267" sStart="null" offset="0" sid="null" wn="4" wnkey="date%1:28:02::" annotator="veweser" text="Nonetheless, the available literature to &lt;b&gt;date&lt;/b&gt; does not support a survival benefit for this therapy." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/cc103.anc" start="13263" end="13267" sStart="null" offset="0" sid="null" wn="4" wnkey="date%1:28:02::" annotator="jeneale" text="Nonetheless, the available literature to &lt;b&gt;date&lt;/b&gt; does not support a survival benefit for this therapy." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/cc103.anc" start="13263" end="13267" sStart="null" offset="0" sid="null" wn="4" wnkey="date%1:28:02::" annotator="a4" text="Nonetheless, the available literature to &lt;b&gt;date&lt;/b&gt; does not support a survival benefit for this therapy." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/cc103.anc" start="13263" end="13267" sStart="null" offset="0" sid="null" wn="4" wnkey="date%1:28:02::" annotator="a3" text="Nonetheless, the available literature to &lt;b&gt;date&lt;/b&gt; does not support a survival benefit for this therapy." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/cc103.anc" start="13263" end="13267" sStart="null" offset="0" sid="null" wn="4" wnkey="date%1:28:02::" annotator="a2" text="Nonetheless, the available literature to &lt;b&gt;date&lt;/b&gt; does not support a survival benefit for this therapy." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/cc103.anc" start="13263" end="13267" sStart="null" offset="0" sid="null" wn="4" wnkey="date%1:28:02::" annotator="a1" text="Nonetheless, the available literature to &lt;b&gt;date&lt;/b&gt; does not support a survival benefit for this therapy." />
    <s path="[OANC]/data/written_2/technical/biomed/cc103.anc" start="26821" end="26832" sStart="null" offset="132" sid="r11.combination.n.0468" wn="1" wnkey="combination%1:14:00::" annotator="adelpriore" text="Indeed, dopamine's multiple effects (even at low doses) make it the perfect pressor/inotropic agent when such a combination is warranted." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/cc103.anc" start="17904" end="17910" sStart="null" offset="0" sid="null" wn="" wnkey="null" annotator="tofox" text="The most a clinician can do is to manage the complications of ARF and limit further renal insult so as to assure the best &lt;b&gt;chance&lt;/b&gt; of renal recovery." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/cc103.anc" start="17904" end="17910" sStart="null" offset="0" sid="null" wn="4 5" wnkey="null" annotator="comcgeetubb" text="The most a clinician can do is to manage the complications of ARF and limit further renal insult so as to assure the best &lt;b&gt;chance&lt;/b&gt; of renal recovery." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/cc103.anc" start="17904" end="17910" sStart="null" offset="0" sid="null" wn="" wnkey="null" annotator="chisom" text="The most a clinician can do is to manage the complications of ARF and limit further renal insult so as to assure the best &lt;b&gt;chance&lt;/b&gt; of renal recovery." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/cc103.anc" start="3386" end="3392" sStart="null" offset="0" sid="null" wn="2" wnkey="become%2:42:01::" annotator="veweser" text="These agents have &lt;b&gt;become&lt;/b&gt; the most widely used for the indications considered in this review." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/cc103.anc" start="3386" end="3392" sStart="null" offset="0" sid="null" wn="1" wnkey="become%2:30:00::" annotator="tofox" text="These agents have &lt;b&gt;become&lt;/b&gt; the most widely used for the indications considered in this review." />
    <s path="[OANC]/data/written_2/technical/biomed/cc103.anc" start="11341" end="11347" sStart="null" offset="82" sid="r9.appear.v.0829" wn="1" wnkey="appear%2:39:00::" annotator="veweser" text="The results of a small level V study by Palmieri et al [ 26] appear to suggest that dopamine may be useful in shortening the recovery time from interleukin-2-induced ARF." />
    <s path="[OANC]/data/written_2/technical/biomed/cc103.anc" start="20822" end="20829" sStart="null" offset="127" sid="r9.appear.v.0836" wn="1" wnkey="appear%2:39:00::" annotator="brubin" text="Although the pathogenesis of renal injury secondary to radiocontrast agents is not entirely understood, it appears to be due to medullary ischemia [ 3, 50]." />
    <s path="[OANC]/data/written_2/technical/biomed/cc103.anc" start="29434" end="29440" sStart="null" offset="168" sid="r9.appear.v.0820" wn="1" wnkey="appear%2:39:00::" annotator="brubin" text="1. For prophylaxsis against radiocontrast-induced ATN, saline infusion should be administered for optimal hydration; neither diuretics nor dopamine appear effective and may be harmful." />
    <s path="[OANC]/data/written_2/technical/biomed/cc103.anc" start="19147" end="19153" sStart="null" offset="41" sid="r9.appear.v.0946" wn="1" wnkey="appear%2:39:00::" annotator="anfahmy" text="In this regard, loop diuretics appear to be more effective and less toxic when given as a continuous infusion rather than as a bolus." />
    <s path="[OANC]/data/written_2/technical/biomed/cc103.anc" start="10073" end="10080" sStart="null" offset="49" sid="r11.absence.n.0233" wn="1" wnkey="absence%1:26:00::" annotator="anfahmy" text="Given these considerations, and in the absence of clinical data, diuretics cannot be recommended to prevent ATN." />
  </sentences>
</list>